Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for Trials
Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses large studies and their tendencies to not group patients by subtypes. Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
